Table 4 Treatments and outcome of COVID-19 pneumonia and other viral pneumonia
Measures | COVID-19 pneumonia (n = 40) | Viral pneumonia (n = 284) | P |
|---|---|---|---|
Antiviral therapy [Yes, n (%)] | 14 (35.0) | 71 (25.0) | 0.178 |
 Lopinavir–ritonavir | 9 (22.5) | 0 (0.0) | < 0.001 |
 Ribavirin | 4 (10.0) | 2 (0.7) | < 0.001 |
 Arbidol | 1 (2.5) | 0 (0.0) | 0.252 |
 Oseltamivir | 1 (2.5) | 65 (22.9) | 0.003 |
 Paramive | 0 (0.0) | 4 (1.4) | 1.000 |
 Others | 0 (0.0) | 3 (1.1) | 1.000 |
Interferon alfa [n (%)] | 38 (95.0) | 15 (5.3) | < 0.001 |
Antibiotic therapy [Yes, n (%)] | 8 (20.0) | 261 (91.9) | < 0.001 |
 None | 32 (80.0) | 23 (8.1) | < 0.001 |
 One kind | 4 (10.0) | 151 (53.2) | |
 Two kinds | 3 (4.7) | 99 (34.9) | |
 Three or more kinds | 1 (2.5) | 11 (3.9) | |
Corticosteroids [n (%)] | 1 (2.5) | 50 (17.6) | 0.014 |
Immunoglobulin [n (%)] | 1 (2.5) | 39 (13.7) | 0.043 |
Blood transfusion [n (%)] | 1 (2.5) | 4 (1.4) | 1.000 |
Oxygen support [n (%)] | |||
 None | 39 (97.5) | 238 (83.8) | 0.024 |
 Nasal catheter, mask or other | 0 (0.0) | 22 (7.7) | |
 Non-invasive ventilation | 0 (0.0) | 8 (2.8) | |
 Invasive mechanical ventilation | 1 (2.5) | 16 (5.6) | |
Mortality [n (%)] | 0 (0.0) | 1 (0.4) | 1.000 |
Required ICU support [n (%)] | 1 (2.5) | 32 (11.3) | 0.047 |
Symptomatic duration [d, median (IQR)] | 5 (0–8) | 8 (4–12) | < 0.001 |
Hospital stay [d, median (IQR)]a | 15 (10–23) | 6 (5–8) | < 0.001 |